Connect Biopharma Holdings LTD 8-K filings

Connect Biopharma announced second quarter 2026 financial results, highlighting the completion of enrollment in Phase 2 Seabreeze STAT studies for asthma and COPD exacerbations, with topline results expected in September 2026.

Connect Biopharma announced its first quarter 2026 financial results, highlighting progress in its rademikibart clinical trials and a successful private placement financing.

Connect Biopharma's Phase 2 Seabreeze STAT trials for asthma and COPD will proceed without sample size changes following a positive interim analysis by the Data Monitoring Committee.

Connect Biopharma secured a $20.2 million private placement and reported encouraging IV rademikibart Phase 1 asthma/COPD data alongside strong 52-week Phase 3 atopic dermatitis results from partner Simcere.

Dr. Kan Chen has resigned from Connect Biopharma's Board of Directors, citing the company's successful strategic shift to a U.S.-centric model.

Connect Biopharma reported increased net losses in Q3 2025 despite progress in its rademikibart clinical trials and regulatory acceptance in China.

Connect Biopharma's CEO and President acquired significant shares, signaling confidence in the company's future.

Connect Biopharma reported a net loss of $12.9 million for Q2 2025, a significant shift from net income in the prior year, while advancing its clinical pipeline and announcing plans to terminate its ADR program for a direct Nasdaq listing.

Connect Biopharma Holdings Limited has expanded its Board of Directors to seven members and appointed experienced biopharmaceutical executive James A. Schoeneck as an independent director.

Connect Biopharma Holdings Limited announced the termination of its American Depositary Receipt (ADR) program and plans for a direct listing of its ordinary shares on Nasdaq under the existing symbol CNTB.

A biopharmaceutical company has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.

Connect Biopharma announced that its exclusive licensee in China, Simcere Pharmaceutical, has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China for the treatment of atopic dermatitis in adults and adolescents.

Connect Biopharma announced its Q1 2025 financial results, highlighting progress in its rademikibart clinical development program and a strong cash position.

Connect Biopharma has commenced a Phase 2 clinical trial to assess rademikibart as a treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD).

Connect Biopharma has commenced a Phase 2 clinical trial to assess the safety and efficacy of rademikibart in treating acute asthma exacerbations.

Connect Biopharma announced positive feedback from the FDA regarding its plan to initiate parallel Phase 2 trials of rademikibart for patients with moderate-to-severe asthma or COPD experiencing acute exacerbations.

Connect Biopharma announced its 2024 financial results and provided a business update, highlighting progress with its rademikibart clinical program and a strengthened leadership team.